Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

CHANGE OF DATE OF BOARD MEETING

Reference is made to the announcement of Fusen Pharmaceutical Company Limited (the "**Company**") dated 18 March 2025 in relation to the holding of a meeting of the board of directors (the "**Board**") of the Company on Friday, 28 March 2025 (the "**Board Meeting**") for the purposes of, among other things, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2024 (the "**2024 Annual Results**") and publication thereof, and considering the payment of a final dividend, if any.

As additional time is required for finalising the 2024 Annual Results, the Board hereby announces that the Board Meeting will be postponed to Monday, 31 March 2025.

By Order of the Board
Fusen Pharmaceutical Company Limited
Cao Zhiming
Chairman and Executive Director

Hong Kong, 26 March 2025

As at the date of this announcement, the Board of the Company comprises Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfeng and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.